A carregar...
Caplacizumab: First Global Approval
Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody(®) caplacizumab (Cablivi™) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Based on positive results in phase II and III trials in patients with aTTP, caplacizumab was recently approved in the E...
Na minha lista:
| Publicado no: | Drugs |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6280848/ https://ncbi.nlm.nih.gov/pubmed/30298461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-018-0989-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|